RXRX Recursion Pharmaceuticals Inc

$RXRX Someone is scared… 🚀 Short interest plunged 20.8M shares (−11.63%), from 178.7M to 157.9M as of Sept. 30! Days to cover dropped from 12.56 to 6.13. Bulls gaining momentum ahead of November’s REC-4881 catalyst! 🔥

$RXRX that dip this morning was fo flush out retail positions so market makers, tutes, and hedges can get more shares for cheap. Welcome to wallstreet. Hold those shares

$RXRX It will be sweet for those of us who have been here more than 2 yrs to see this @ $43 instead of $4.30 in 2027😂🚀

$RXRX Been saying this for a long time. Patience is the key. Not talking about bullshit actions at this stage ups/downs

🚀 $RXRX could be one of the most underrated AI opportunities in biotech. Most investors are focused on AI chatbots and chips. Meanwhile, Recursion is using AI to tackle something far more valuable: discovering new medicines. This isn't just AI hype. Recursion is running millions of real biological experiments, building massive proprietary datasets, and using AI to discover disease targets and design new drugs. ✅ Genentech advancing an AI-discovered neuroscience target ✅ Promising Phase 2 results from REC-4881 ✅ AI-driven drug design accelerating discovery ✅ Partnerships with major pharmaceutical companies ✅ A continuously improving AI platform powered by real laboratory data The real opportunity isn't just one successful drug. It's building an AI-powered discovery engine capable of producing many. AI is transforming software. $RXRX is betting it can transform medicine. I'm bullish on the long-term potential. 🔥 #$RXRX #AI #Biotech #DrugDiscovery

$RXRX 💎 Worth noting: NVIDIA Senior Account Manager David Klein congratulated Najat and the team on LinkedIn, calling the news “incredible” and “a testament to the incredible team at Recursion.” Encouraging industry recognition—though a personal comment

$RXRX They just proved that have a drug making pipeline. They proved AI can successfully create new medicine. THIS IS HUGE. I suspect we see a big pump and short covering.

$RXRX The new shares represent 11.5% increase in share count. They bought at 3.25/share. We got positive clinical results, and more news pending 3.25 level will likely hold strongly if price gets down there again. If we get good news nov 2, bye bye 3s, and maybe 4s forever

$RXRX TP increased Morgan Stanley analyst Sean Laaman raised the firm's price target on Recursion Pharmaceuticals to $5.90 from $5.30 and keeps an Equal Weight rating on the shares (found now on X need to find the correct source)

$RXRX Are the remaining short sellers comfortable holding through November 2? Approximately 158 million shares are STILL short. That’s an enormous amount of potential future buying if shorts decide to cover.

$RXRX Nice day to add some more. One of these days between now until Nov 2 they will drop some news and you will never see these levels again.

$RXRX it’s crazy how it dipped and ripped this morning. Sorry if your stop loss was triggered. Price is still cheap long term

$RXRX $TEM Recursion: The company has extended its partnership with Tempus through November 2029. Tempus will also license Recursion's RNA foundation model. This is meaningful evidence that Recursion's AI technology has potential commercial uses beyond its own drug pipe

$RXRX started my position at opening today , just 200 shares but felt like the timing was right. Waiting to add. Happy to join you all.

$RXRX all news is positive. Pipeline is progressing and they are converting on their partnerships with MAJOR Pharma. Millions of $$ in milestones. Really NOTHING negative other than share count. This downward pressure is not justified. Sky is the limit for this company. Next Amgen or Lilly. Needs to get some love here.

$RXRX just the beginning of ai drug discovery mania, isomorphic 50 bln valuation. Recursion more mature than peers, if rec 4881 gets fda alignment than 0 to 100 real quick . Think of quantum stoks summer 24, they were under 1 and mostly all min 10x now. And ai drug discovery is going to get additional government attention because this sector will not get any negative ai news . My guess early next year either anthropic or isomorphic will buy them , maybe the latter because they are more clinical focused. Anthropic buyout maybe not easy . I think isomorphic lab will buy rxrx next year, 40 bln loading. Game on guys . Why 40 bln ? They are the most complete ai drug discovery company . Think of tesla amazon meta quantum in early days, rxrx has the potential to be there, so 40 bln seems cheap. Isomorphic talks about curing all diseases , this will 🚀 patient for few more months. Hope nov 2 doesnt disappoint.

$RXRX Wow, since when did we get such foolish bears posting here? Cathie Wood's ARK reportedly purchased approximately 1.9 million RXRX shares yesterday, following another reported purchase of 1.5 million earlier in the week.

$RXRX This is NOT just a stock offering. It’s a $200 MILLION OVERSUBSCRIBED offering! 🔥 OVERSUBSCRIBED means institutional investor demand EXCEEDED the shares available. And here’s what’s even more interesting: ARK Invest bought $RXRX on October 5, 6, and 7, and is now among the institutional investors participating in the offering!

$RXRX A $200M oversubscribed public offering speaks volumes about institutional demand! Oversubscribed means demand exceeded the shares offered. Janus Henderson, Invus, ARK Invest, and other major investors are stepping up while RXRX advances its pipeline. Strong institutional demand + funding runway into 2029 + major clinical catalysts ahead. 🧬🔥 This is more than just raising capital. It’s a strong vote of confidence in RXRX’s future.

$RXRX Problem is you all are attached to this one stock. You are NOT looking at the big picture/ the whole market dynamics, and what is happening behind the scenes. That is why they say, "LOVE IS BLIND". I am just as BULLISH as every TOM, DICK and HARRY following this stock, but you got to learn to risk manage and act only when all the factors align. Again- the alignment won't happen until next week.